Drug targeting to endothelial cells (EC) will help to attain more specific and effective treatment of a plethora of maladies including inflammation. We found that targeting prototype nanocarriers and cargoes to the endothelial Cell Adhesion Molecules (CAMs) ICAM-1 and VCAM-1, differentially expressed by resting vs pathologically altered EC, provides prophylactic and therapeutic drug delivery into EC. Further, ICAM-targeted nanoparticles transfer across EC without damage to the cells. Flow conditions, affinity and geometry of anti-CAM carriers govern their biological behavior, EC targeting and sub-cellular destination. Abnormal flow in pathological vascular sites provides both a stimulus for CAM exposure on EC and a mechanism for local binding of wm to EC. To achieve EC targeting with controlled duration and timing of effects, we propose to target to CAMs novel biocompatible stealth PEG-di-block copolimer nanocarriers with controlled geometry designed by our team: worm micelles (wm), spherical polymersomes (ps) and nanoparticles (np), showing prolonged circulation in animals (unprecedentently achieving weeks for wm, due to their alignment with flow). Our hypothesis is that these nanocarriers will serve as highly effective long-circulating carrier platforms for sustained delivery of drugs to, into and across EC using CAM targeting. Spherical carriers are expected to effectively enter and traverse EC, while wm are expected to recognize vascular pathological sites (vascular surveillance). This will be tested in the following Specific Aims in vitro and in vivo: 1. Refine anti-CAM targeted polymer carriers with controlled geometry/affinity and define their endothelial targeting;2. Define intra-and transcellular transport of these anti-CAM carriers and effects of flow and EC phenotype in control of these processes;3. Evaluate potential side effects and anti-inflammatory utility of these anti-CAM carriers. These studies will provide: i) proof of principle for EC targeting of stealth polymer nanocarriers;and, ii) insight into the role of flow, carrier geometry and affinity in targeting to EC and EC responses (e.g., endocytosis and activation) to targeting. Bearing in mind the central roles of EC as a gate-keeper of vascular transport and as a target and barrier for delivery of drugs for treatment of cardiovascular, oncological, metabolic and other maladies, this is a globally important goal for the field of drug delivery. Public Health Relevance: Targeted delivery of drugs to endothelial cells lining vasculature will advance treatment of many health maladies. In this grant, we will design and test a novel drug delivery platform based on targeted recognition of endothelial surface determinants by polymer nanocarriers loaded by anti-inflammatory and other therapeutic agents.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL087036-05
Application #
8259755
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Danthi, Narasimhan
Project Start
2008-05-01
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2014-04-30
Support Year
5
Fiscal Year
2012
Total Cost
$389,813
Indirect Cost
$142,313
Name
University of Pennsylvania
Department
Pharmacology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Jordan, Carolyn; Shuvaev, Vladimir V; Bailey, Mark et al. (2016) The Role of Carrier Geometry in Overcoming Biological Barriers to Drug Delivery. Curr Pharm Des 22:1259-73
Myerson, Jacob W; Anselmo, Aaron C; Liu, Yaling et al. (2016) Non-affinity factors modulating vascular targeting of nano- and microcarriers. Adv Drug Deliv Rev 99:97-112
Shuvaev, Vladimir V; Muro, Silvia; Arguiri, Evguenia et al. (2016) Size and targeting to PECAM vs ICAM control endothelial delivery, internalization and protective effect of multimolecular SOD conjugates. J Control Release 234:115-23
Han, Jingyan; Shuvaev, Vladimir V; Davies, Peter F et al. (2015) Flow shear stress differentially regulates endothelial uptake of nanocarriers targeted to distinct epitopes of PECAM-1. J Control Release 210:39-47
Brenner, Jacob S; Greineder, Colin; Shuvaev, Vladimir et al. (2015) Endothelial nanomedicine for the treatment of pulmonary disease. Expert Opin Drug Deliv 12:239-61
Shuvaev, Vladimir V; Brenner, Jacob S; Muzykantov, Vladimir R (2015) Targeted endothelial nanomedicine for common acute pathological conditions. J Control Release 219:576-95
Chacko, Ann-Marie; Han, Jingyan; Greineder, Colin F et al. (2015) Collaborative Enhancement of Endothelial Targeting of Nanocarriers by Modulating Platelet-Endothelial Cell Adhesion Molecule-1/CD31 Epitope Engagement. ACS Nano 9:6785-93
Howard, Melissa D; Hood, Elizabeth D; Zern, Blaine et al. (2014) Nanocarriers for vascular delivery of anti-inflammatory agents. Annu Rev Pharmacol Toxicol 54:205-26
Howard, Melissa; Zern, Blaine J; Anselmo, Aaron C et al. (2014) Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm. ACS Nano 8:4100-32
Hood, Elizabeth D; Chorny, Michael; Greineder, Colin F et al. (2014) Endothelial targeting of nanocarriers loaded with antioxidant enzymes for protection against vascular oxidative stress and inflammation. Biomaterials 35:3708-15

Showing the most recent 10 out of 48 publications